Nanoformulation and methods of use of thyroid receptor beta1 agonists for liver targeting
OwnerShaker A. Mousainventor
Life of this patent
Estimating the term…
Abstract
A composition and an associated method for hepatic targeted delivery of thyroid receptor beta1 (TRβ1) agonist to a liver of a subject. The composition includes hydrophobic nanoparticles, a liver targeting moiety exterior to each nanoparticle and covalently bonded to each nanoparticle, and at least one TRβ1 agonist encapsulated within each nanoparticle. The nanoparticles include chitosan hybrid nanoparticles, amine-modified PLGA nanoparticles, solid lipid nanoparticles, and combinations thereof. The liver targeting moiety includes Glycyrrhetinic acid (GA), Lactobionic acid (LA), or combinations thereof.
Claims20
A composition for hepatic targeted delivery of thyroid receptor beta1 (TRβ1) agonist to a liver of a subject, said composition comprising:
- hydrophobic nanoparticles, wherein the nanoparticles are selected from the group consisting of chitosan hybrid nanoparticles, amine-modified poly (lactic-co-glycolic acid) (PLGA) nanoparticles, solid lipid nanoparticles, and combinations thereof;
- a liver targeting moiety exterior to each nanoparticle and covalently bonded to each nanoparticle, said liver targeting moiety selected from the group consisting of Glycyrrhetinic acid (GA), Lactobionic acid (LA), and combinations thereof;
- and
- at least one TRβ1 agonist encapsulated within each nanoparticle, wherein a second dosage, reduced about ten fold from a first dosage, of the TRβ1 agonist in the composition exhibits about a two fold or more total cholesterol lowering in the subject as is exhibited by the first dosage of un-encapsulated TRβ1 agonist.
Dependencies are inferred from the claim text.